Rate of palivizumab administration in accordance with current recommendations among hospitalized children

Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals

“…In this large, population-based study, between a third and 40% of eligible infants were prescribed palivizumab (in main vs sensitivity analyses, respectively). Our findings were comparable to other studies: 47% of 176 eligible infants in Sweden in 2005-2010, 35% of 40 eligible infants in the US in 2000/1 and 41% of 2395 eligible children in Florida received at least one dose of palivizumab; [25][26][27] although a study of eligible infants in NICUs in 2003-13 from Western Australia found that only 9.2% of 2679 infants were treated. 11 During the COVID-19 pandemic, palivizumab treatment has been recommended to all infants with CLD born at ≤34 weeks in the UK.…”

CHD and respiratory syncytial virus: global expert exchange recommendations

“…Voting Results: agree/disagree 7-1; Evidence Grade/Level: 4 15,18,21,24,25,50,[53][54][55][56][57][58][59][60][61] On the basis of clinical experience and a review of the literature, the faculty identified (7-1) a number of barriers to effective respiratory syncytial virus immunoprophylaxis in children with CHDfor example, poor awareness of respiratory syncytial virus infection and disease risks and the burden of disease 55,56,60 were cited and attributed to several factors, including variable definitions of at-risk children, lack of agreement and clarity on a multidisciplinary approach to respiratory syncytial virus immunoprophylaxis, and limited awareness of the impact of respiratory syncytial virus infection among healthcare providers who started their careers after immunoprophylaxis became available. Other respiratory syncytial virus immunoprophylaxis barriers identified included fear of injections, concerns about potential adverse effects related to therapy, and failure, by both healthcare providers and parents, to understand the importance of respiratory syncytial virus immunoprophylaxis regimen completionthat is, administration of all prescribed doses.…”

Evaluation of Compliance With Palivizumab Recommendations in a Multicenter Study of Young Children Presenting to the Emergency Department With Bronchiolitis

“…In contrast to the poor compliance demonstrated in the aforementioned study with ever receiving prophylaxis, 17 an Italian study documented 86% compliance with all doses of palivizumab prophylaxis after initiation of a neonatal intensive care outpatient program. In this Italian cohort, the strongest predictor for not receiving prophylaxis was foreign birth and being a nonnative speaker.…”

“…12 -16 Despite data demonstrating clinical benefit and the AAP recommendation, there has been difficulty ensuring that infants receive the monthly injections during the entire RSV season. 17 As part of an ongoing large multicenter, prospective observational study of children treated in the emergency department (ED) for bronchiolitis, we investigated the compliance with AAP recommendations for palivizumab prophylaxis. …”